• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Intec Announces Secondary Offering of Shares To Fund Clinical Trials

August 16, 2017


Yesterday, Intec Pharma Ltd. (NASDAQ:NTEC) (TASE:NTEC), the clinical-stage biopharmaceutical company developing "AP-CBD/THC", an Accordion Pill containing CBD and THC for various indications including low back neuropathic pain and fibromyalgia, filed to announce the launch of a secondary offering of shares.


Related: How Medical Marijuana Helps Patients with Fibromyalgia


Offering Details


This offering will be an underwritten public offering of ordinary NTEC shares, with Oppenheimer & Co. Inc. acting as the sole book-running manager. In connection with this offering, Intec Pharma will also grant the underwriters a 30-day over-allotment option to purchase up to an additional 15% of the number of ordinary shares being offered.


Related: How Intec's Accordion Pill Helps Cannabinoid Absorbtion


According to the prospectus in the Form F-3 that Intec filed with the SEC back in June, Intec "may offer and sell from time to time in one or more series or issuances, and on terms that we will determine at the time of the offering, ordinary shares, warrants, subscription rights, debt securities and/or units consisting of two or more of these classes or series of securities up to an aggregate amount of $100,000,000."


Related: 7 Key Takeaways from Intec's Earnings


Intec won't actually be raising $100,000,000 though. This morning, StreetInsider reported that Intec would be selling approximately $10.6 million shares at an offering price of $4.70 per share. At the time of writing this, shares of NTEC are trading at $5.40 per share. "The gross proceeds of the offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses."


Related: Intec Appoints Life Sciences Veteran as New CEO


For more cannabinoid biotech stocks, check out our biotech marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram






Before buying any ordinary shares of Intec Pharma in the offering, you should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that you should consider when making your investment decision. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these ordinary shares may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York, 10004, or by telephone, at 212-667-8563, or e-mail at EquityProspectus@opco.com.


This article does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.